Tuberculosis News and Research

Latest Tuberculosis News and Research

WFP appeals for $5.2m to feed at least 500,000 Malawaians through Dec. 2010

The U.N.'s World Food Programme (WFP) made an international appeal Thursday for $5.2 million to help feed more than half a million people in Malawi through the end of next year, Agence France-Presse reports.

14 Sep 2009

Study identifies causes, rates of death among young people worldwide

"Road accidents, pregnancy and childbirth complications, suicide, violence, the AIDS virus and tuberculosis are the biggest killers of young people across the world," according to a paper published on Friday in the journal Lancet, Reuters reports.

11 Sep 2009

Quintiles partners with the University of Pretoria

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University of Pretoria as part of its industry unique Prime Site program, an initiative to accelerate the development of new and more effective medicines.

11 Sep 2009

Preventive-care TB therapy is cost-effective for patients

University of Alabama at Birmingham (UAB) researchers have found that the cost of preventive antibiotic tuberculosis (TB) therapy for patients infected by human immunodeficiency virus (HIV) is generally less expensive than the reported cost of treating newly confirmed TB cases.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Biomagnetics Diagnostics deploys IOBS testing technology

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced its entry into the Integrated Optical Biosensor System (IOBS) market. IOBS are a relatively new classification of pathogen detection equipment which use advanced fiber optic-based technology to detect a wide variety of human and animal pathogens.

9 Sep 2009

African health ministers adopt resolutions to improve health as WHO regional meeting closes

At the conclusion of the 59th session of the WHO Regional Committee for Africa, African health ministers agreed on four resolutions that aim to improve health on the continent, the Guardian reports.

8 Sep 2009

Exhibition on history of immunology to be presented at 2nd European Congress of Immunology

An exhibition entitled "The Birth of Immunology" during the 2nd European Congress of Immunology from13th to 16th September 2009 at the main foyer of the ICC in Berlin will offer insights into the fast-paced history of immunology. Immunology has promoted medical progress since the end of the 19th century like almost no other discipline.

8 Sep 2009

Opinion: Local drug production in developing countries; Obama's PEPFAR changes

The international community focuses on lowering drug prices as a means of improving access and "today its idea is local pharmaceutical production .

5 Sep 2009

Also in global health news: Africa measles eradication; water, food security in South Asia; MDR-TB in Mumbai; SADC summit; U.S. Cuba embargo

WHO Regional Director for Africa Luis Gomes Sambo said Tuesday during the 59th Session of the WHO Regional Committee for Africa in Kigali, Rwanda, that measles could be eradicated from the continent by 2020, citing an 89 percent reduction in the number of deaths caused by measles between 2000 and 2007, Angencia AngolaPress reports.

4 Sep 2009

Increase in Rifampicin dosage shortens tuberculosis treatment duration

According to Dutch researcher Hanneke Later-Nijland, it may be possible to shorten the duration of treatment for tuberculosis. Due to the long duration of treatment, not every patient sees it through. Partly because of this, tuberculosis is one of the most lethal diseases in developing countries.

3 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Also in Global Health news: Flu, cholera in PNG; improving life awards; HIV/AIDS in Rwanda; men and maternal/child health; MDR-TB in India

"Twin outbreaks of a flu-like illness and dysentery in a remote region of Papua New Guinea have killed 47 people and infected another 2,000 villagers, a senior medical official said Monday," Agence France-Presse reports. According to provincial health adviser Doctor Theo Likei, the WHO has collected and is testing samples of the virus from the "stricken villages" (8/31). Additionally, the country is experiencing a cholera outbreak - "the first time the disease has officially been confirmed in the country," the BBC reports (Mercer, 8/31).

1 Sep 2009

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass' proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential.

31 Aug 2009

Also in Global Health news: ARVs in Uganda; Brazil's fight against HIV/AIDS

Zainab Akol, Uganda's AIDS Control Program director, said the health ministry has acquired enough antiretroviral (ARV) drugs to provide treatment for people living with HIV/AIDS until the end of the year, New Vision reports. In addition to 30 tons of drugs, the ministry received at the beginning of August from the Global Fund to Fight AIDS, Tuberculosis and Malaria, it also purchased ARVs worth about $20 million this month, Akol said (Kagolo, 8/27).

29 Aug 2009

Urine LAM-ELISA's sensitivity of 50.7% in identifying TB disappoints

Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis (TB). A trial of the new diagnostic, described in the open access journal BMC Infectious Diseases found that it was only capable of identifying 50.7% of TB cases.

28 Aug 2009

Enzymes could be targeted to kill dangerous pathogens

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens.

28 Aug 2009

Also in global health news: NTD study; false cholera cases in Zimbabwe; contaminated water in Kenya; doctor's strike ends

UPI reports on a recent review article in the journal PLoS Neglected Tropical Diseases that analyzed the toll of neglected tropical diseases on populations in sub-Saharan Africa. "Researchers said helminth (parasitic worm) infections account for approximately 85 percent of the neglected tropical diseases, which overall might be equivalent to more than double that caused by tuberculosis and as much as half of the area's malaria disease burden," the news service writes (8/26).

28 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Tuberculosis News and Research

Latest Tuberculosis News and Research

WFP appeals for $5.2m to feed at least 500,000 Malawaians through Dec. 2010

Study identifies causes, rates of death among young people worldwide

Quintiles partners with the University of Pretoria

Preventive-care TB therapy is cost-effective for patients

Merck's GARDASIL receives approval from FDA Advisory Committee

Biomagnetics Diagnostics deploys IOBS testing technology

African health ministers adopt resolutions to improve health as WHO regional meeting closes

Exhibition on history of immunology to be presented at 2nd European Congress of Immunology

Opinion: Local drug production in developing countries; Obama's PEPFAR changes

Also in global health news: Africa measles eradication; water, food security in South Asia; MDR-TB in Mumbai; SADC summit; U.S. Cuba embargo

Increase in Rifampicin dosage shortens tuberculosis treatment duration

Cimzia approved for treating adult patients with rheumatoid arthritis

Also in Global Health news: Flu, cholera in PNG; improving life awards; HIV/AIDS in Rwanda; men and maternal/child health; MDR-TB in India

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

Also in Global Health news: ARVs in Uganda; Brazil's fight against HIV/AIDS

Urine LAM-ELISA's sensitivity of 50.7% in identifying TB disappoints

Enzymes could be targeted to kill dangerous pathogens

Also in global health news: NTD study; false cholera cases in Zimbabwe; contaminated water in Kenya; doctor's strike ends

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Tuberculosis News and Research

Latest Tuberculosis News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in